APA (7th ed.) Citation

Dinneen, E., Almeida-Magana, R., Al-Hammouri, T., Pan, S., Leurent, B., Haider, A., . . . Jenkins, K. (2025). Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): A multicentre, patient-blinded, randomised, controlled phase 3 trial. The lancet oncology, 26(4), 447-458. https://doi.org/10.1016/S1470-2045(25)00091-9

Chicago Style (17th ed.) Citation

Dinneen, Eoin, et al. "Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial." The Lancet Oncology 26, no. 4 (2025): 447-458. https://doi.org/10.1016/S1470-2045(25)00091-9.

MLA (9th ed.) Citation

Dinneen, Eoin, et al. "Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial." The Lancet Oncology, vol. 26, no. 4, 2025, pp. 447-458, https://doi.org/10.1016/S1470-2045(25)00091-9.